 Virpax Pharmaceuticals Inc NASDAQ: VRPX expanded its exclusive license agreement for AnQlar with Nanomerics Ltd, providing Virpax with the worldwide rights for development and commercialization. Virpax has completed in-vitro, ex-vivo human mucosal cells, and in-vivo rats. 